**Supplementary Methods**

*Boolean Search:*

PubMed was accessed and queried on January 7, 2019. Boolean search terms were: (checkpoint OR costimula\* OR co-stimula\* OR nivolumab OR pembrolizumab OR avelumab OR atezolizumab OR PD-1 OR PD1 OR durvalumab OR PD-L1 OR PDL1 OR ipilimumab OR tremelimumab OR CTLA-4 OR CTLA4 OR OX40 OR 4-1BB OR GITR

OR CD27 OR CD40 OR ICOS) AND (adverse event\* OR adverse reaction OR toxicit\* OR irAE OR neurological OR hypophysitis OR encephalopathy OR meningitis OR thyroid\* OR adrenal OR pneumonitis OR colitis OR dermatologic OR cutaneous OR

vitiligo OR myocarditis OR arthritis OR neuropathy OR myopathy OR sarcoidosis OR nephr\*) AND (delay\* OR late OR timing OR after OR following OR year\* OR months OR weeks) NOT allerg\* NOT pollut\* NOT mice NOT mouse NOT murine NOT rat NOT

rats NOT monkey\* NOT pig NOT bovine NOT rabbit NOT fetal NOT neonatal NOT pregnan\* NOT miscarriage NOT menopaus\* NOT particle\* NOT nanoparticle\* NOT hydrocarbon NOT vitro[Title] NOT vivo[Title] NOT preclinical[Title] NOT GVHD[Title] ] NOT graft[Title] NOT host[Title] NOT transplan\*[Title] NOT reject\*[Title] NOT allogeneic[Title] NOT allograft[Title].

*Titles Keyword Screen:*

“checkpoint inhibitor” or “costimulatory agonist” or “immunotherapy” or any recognized immunotherapeutic agent in the context of cancer treatment.